We found that VEGF-C overexpression partially recovered bladder cancer cell sensitivity to cisplatin compared the VEGF-C control with IC50 values of10.05 ± 1.05 mg/l and 3.14 ± 1.02 mg/l to 0.63 ± 0.16 mg/l, respectively (Fig. 6A, 6B). The gene discussed is VEGFC; the disease is urinary bladder cancer.